These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35891442)

  • 21. Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: A cohort study and a meta-analysis.
    Auroux M; Laurent B; Coste B; Massy E; Mercier A; Durieu I; Confavreux CB; Lega JC; Mainbourg S; Coury F
    Joint Bone Spine; 2022 Oct; 89(5):105380. PubMed ID: 35490940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity of the mRNA-1273 and ChAdOx1 nCoV-19 vaccines in Asian patients with autoimmune rheumatic diseases under biologic and/or conventional immunosuppressant treatments.
    Liao HT; Tung HY; Chou CT; Tsai HC; Yen YN; Tsai CY
    Scand J Rheumatol; 2022 Nov; 51(6):500-505. PubMed ID: 35638589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2-specific T-cell responses after COVID-19 recovery in patients with rheumatic diseases on immunosuppressive therapy.
    Lledó A; Retuerto M; Almendro-Vázquez P; Fernández-Ruiz M; Galindo M; Laguna-Goya R; Paz-Artal E; Lalueza A; Aguado JM; Pablos JL
    Semin Arthritis Rheum; 2021 Dec; 51(6):1258-1262. PubMed ID: 34775160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The protective effect of rheumatic disease agents in COVID-19.
    Valenzuela-Almada MO; Putman MS; Duarte-García A
    Best Pract Res Clin Rheumatol; 2021 Mar; 35(1):101659. PubMed ID: 33526326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland.
    Bjornsson AH; Grondal G; Kristjansson M; Jonsdottir T; Love TJ; Gudbjornsson B;
    Ann Rheum Dis; 2021 May; 80(5):671-672. PubMed ID: 33402343
    [No Abstract]   [Full Text] [Related]  

  • 26. Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations.
    Kroon FPB; Najm A; Alunno A; Schoones JW; Landewé RBM; Machado PM; Navarro-Compán V
    Ann Rheum Dis; 2022 Mar; 81(3):422-432. PubMed ID: 34876462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 and Disease-Modifying Anti-rheumatic Drugs.
    D'Silva KM; Wallace ZS
    Curr Rheumatol Rep; 2021 Apr; 23(5):28. PubMed ID: 33893890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19: autoimmunity, multisystemic inflammation and autoimmune rheumatic patients.
    Szekanecz Z; Balog A; Constantin T; Czirják L; Géher P; Kovács L; Kumánovics G; Nagy G; Rákóczi É; Szamosi S; Szűcs G; Vályi-Nagy I
    Expert Rev Mol Med; 2022 Mar; 24():e13. PubMed ID: 35311631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of biologic and conventional disease-modifying antirheumatic drugs on COVID-19 incidence among rheumatic patients during the first and second wave of the pandemic in Iran.
    Sahebari M; Mirfeizi Z; Shariati-Sarabi Z; Dadgar Moghadam M; Hashemzadeh K; Firoozabadi M
    Reumatologia; 2022; 60(4):231-241. PubMed ID: 36186839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection. Colombian Association of Rheumatology.
    Saldarriaga Rivera LM; Fernández Ávila D; Bautista Molano W; Jaramillo Arroyave D; Bautista Ramírez AJ; Díaz Maldonado A; Hernán Izquierdo J; Jáuregui E; Latorre Muñoz MC; Restrepo JP; Segura Charry JS
    Reumatol Clin (Engl Ed); 2020; 16(6):437-446. PubMed ID: 32800760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases.
    Hasseli R; Mueller-Ladner U; Hoyer BF; Krause A; Lorenz HM; Pfeil A; Richter J; Schäfer M; Schmeiser T; Strangfeld A; Schulze-Koops H; Voll RE; Specker C; Regierer AC
    RMD Open; 2021 Jan; 7(1):. PubMed ID: 33479021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs.
    Yousefghahari B; Navari S; Sadeghi M; Soleimaniamiri S; Soleimaniamiri M; Heidari B; Babaei M; Ghodrati K; Guran A; Gholinia H
    Clin Rheumatol; 2021 Oct; 40(10):4309-4315. PubMed ID: 34052904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 infection among patients with systemic autoimmune diseases.
    Emmi G; Bettiol A; Mattioli I; Silvestri E; Di Scala G; Urban ML; Vaglio A; Prisco D
    Autoimmun Rev; 2020 Jul; 19(7):102575. PubMed ID: 32376395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments.
    Ferri C; Giuggioli D; Raimondo V; L'Andolina M; Dagna L; Tavoni A; Caso F; Ursini F; Ruscitti P; Caminiti M; Foti R; Riccieri V; Guiducci S; Pellegrini R; Zanatta E; Varcasia G; Olivo D; Gigliotti P; Cuomo G; Murdaca G; Cecchetti R; De Angelis R; Romeo N; Ingegnoli F; Cozzi F; Codullo V; Cavazzana I; Colaci M; Abignano G; De Santis M; Lubrano E; Fusaro E; Rossa AD; Spinella A; Lumetti F; De Luca G; Bellando-Randone S; Visalli E; Dal Bosco Y; Amato G; Giannini D; Bilia S; Masini F; Pellegrino G; Pigatto E; Generali E; Mariano GP; Pettiti G; Zanframundo G; Brittelli R; Aiello V; Caminiti R; Scorpiniti D; Ferrari T; Campochiaro C; Brusi V; Fredi M; Moschetti L; Cacciapaglia F; Gragnani L; Monti M; Lorini S; Paparo SR; Ragusa F; Mazzi V; Elia G; Ferrari SM; Di Cola I; Vadacca M; Lorusso S; Barsotti S; Aprile ML; Marco T; Miccoli M; Bosello S; Matucci-Cerinic M; D'Angelo S; Doria A; Franceschini F; Meliconi R; Iannone F; Giacomelli R; Zignego AL; Fallahi P; Antonelli A
    Curr Pharm Des; 2021; 27(41):4245-4252. PubMed ID: 34477509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency and severity of COVID-19 in patients treated with biological disease-modifying anti-rheumatic drugs for inflammatory rheumatic disease: a cross-sectional study.
    Lohse A; Bossert M; Bozgan AM; Charpentier A; Guillochon C; Bourgoin C; Balblanc JC; Conrozier T
    Clin Exp Rheumatol; 2020; 38(6):1273. PubMed ID: 33253100
    [No Abstract]   [Full Text] [Related]  

  • 36. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study.
    Talamonti M; Galluzzo M; Chiricozzi A; Quaglino P; Fabbrocini G; Gisondi P; Marzano AV; Potenza C; Conti A; Parodi A; Piaserico S; Bardazzi F; Argenziano G; Rongioletti F; Stingeni L; Micali G; Loconsole F; Rossi MT; Bongiorno MR; Feliciani C; Rubegni P; Amerio P; Fargnoli MC; Pigatto P; Savoia P; Nisticò SP; Giustini S; Carugno A; Cannavo' SP; Rech G; Prignano F; Offidani A; Lombardo M; Zalaudek I; Bianchi L; Peris K; ; Balestri R ; Bernardini N ; Belloni Fortini A ; Burlando M ; Caldarola G ; Campione E ; Cattaneo A ; Dapavo P ; Dastoli S ; De Simone C ; Di Nuzzo S ; Diotallevi F ; Fierro MT ; Franchi C ; Esposito M ; Foti C ; Gambini DM ; Gambardella A ; Girolomoni G ; Giunta A ; Guarneri C ; Gualdi G ; Hansel K ; Megna M ; Mugheddu C ; Musumeci ML ; Patrizi A ; Pellacani G ; Richetta AG ; Rosi E ; Sacchelli L ; Tiberio R ; Tilotta G ; Trovato E ; Venturini M ; Vezzoni R
    Expert Opin Biol Ther; 2021 Feb; 21(2):271-277. PubMed ID: 33216643
    [No Abstract]   [Full Text] [Related]  

  • 37. Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors.
    Jovani V; Calabuig I; Peral-Garrido ML; Tovar-Sugrañes E; López-González MD; Bernabeu P; Martínez A; Esteve-Vives J; León-Ramírez JM; Moreno-Perez O; Boix V; Gil J; Merino E; Vela P; Andrés M
    Ann Rheum Dis; 2022 Jul; 81(7):e131. PubMed ID: 32586922
    [No Abstract]   [Full Text] [Related]  

  • 38. The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study.
    Favalli EG; Gobbini A; Bombaci M; Maioli G; Biggioggero M; Pesce E; Favalli A; Martinovic M; Fabbris T; Marchisio E; Bandera A; Gori A; Abrignani S; Grifantini R; Caporali R
    Front Med (Lausanne); 2022; 9():850858. PubMed ID: 35360719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Seroprevalence and clinical outcomes of SARS-CoV-2 in paediatric patients with rheumatic disease.
    Walters HM; Mian Z; Thomas L; Cerise J; Eberhard BA; Pagano E; Gottlieb BS; Steigerwald K; Hui-Yuen JS
    Rheumatology (Oxford); 2022 Jun; 61(SI2):SI112-SI119. PubMed ID: 34599820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of Severe COVID-19 Infection in Patients With Inflammatory Rheumatic Diseases.
    Bachiller-Corral J; Boteanu A; Garcia-Villanueva MJ; de la Puente C; Revenga M; Diaz-Miguel MC; Rodriguez-Garcia A; Morell-Hita JL; Valero M; Larena C; Blazquez-Cañamero M; Guillen-Astete CA; Garrote S; Sobrino C; Medina-Quiñones C; Vazquez-Diaz M
    J Rheumatol; 2021 Jul; 48(7):1098-1102. PubMed ID: 33722949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.